Related Experiment Video
Updated: Aug 26, 2026

Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
MR-guided radiofrequency ablation of hepatic malignancies at 1.5 T: initial results
Andreas H Mahnken1, Arno Buecker, Elmar Spuentrup
1Department of Diagnostic Radiology, Aachen University of Technology, Aachen, Germany. mahnken@rad.rwth-aachen.de
Purpose:
To assess the feasibility of magnetic resonance (MR)-guided radiofrequency ablation (RFA) of hepatic malignancies using a high-field MR scanner.
Materials And Methods:
A total of 10 patients with 14 primary (N = 1) or secondary (N = 13) hepatic malignancies underwent MR-guided RFA using a closed-bore 1.5 T MR scanner. Lesion diameters ranged from 2.0 cm to 4.7 cm. RFA was performed using a 200-W generator in combination with a 3.5-cm LeVeen electrode applying a standardized energy protocol.
Results:
RFA was technically feasible in all patients. Necrosis diameter ranged from 2.5 cm to 6.8 cm. The mean follow-up period is 12.2 (1-18) months. In nine out of 10 patients, local tumor control was achieved. For this purpose, a second CT-guided RFA was required in two patients. In four patients, multifocal hepatic tumor progression occurred, with the treated lesion remaining tumor-free in three of these patients. Two patients showed extrahepatic tumor progression. Four patients remained tumor-free. No major complications occurred.
Conclusion:
MR-guided RFA of hepatic malignancies in a closed-bore high-field MR scanner is technically feasible and safe. It can be advantageous in locations considered unfavorable for CT-guided puncture or in patients in which iodinated contrast material is contraindicated.
More Related Videos
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023